Novo Nordisk A/S Company Profile (NYSE:NVO)

About Novo Nordisk A/S

Novo Nordisk A/S logoNovo Nordisk A/S is a healthcare company. The Company is engaged in discovery, development, manufacturing and marketing of pharmaceutical products. The Company's business segments include diabetes and obesity care, and biopharmaceuticals. The diabetes and obesity care segment covers insulins, glucagon-like peptide-1 (GLP-1), other protein-related products (such as glucagon, protein-related delivery systems and needles), oral anti-diabetic drugs and obesity. The biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy. It offers a range of diabetes product, including new generation insulins and a portfolio of modern insulin. It provides Saxenda, which is a product to treat obesity and is available in Denmark, Italy and Canada. Its other products/compounds include Xultophy, Semaglutide (NN9535), Faster-acting insulin aspart (NN1218), N9-GP (NN7999), N8-GP (NN7088) and NN8640 Once-weekly human growth hormone.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Drug Manufacturers - Other
  • Sub-Industry: N/A
  • Exchange: NYSE
  • Symbol: NVO
  • CUSIP:
Key Metrics:
  • Previous Close: $35.78
  • 50 Day Moving Average: $35.29
  • 200 Day Moving Average: $38.79
  • 52-Week Range: $30.89 - $57.81
  • Trailing P/E Ratio: 16.67
  • Foreward P/E Ratio: 14.79
  • P/E Growth: 1.68
  • Market Cap: $89.60B
  • Outstanding Shares: 2,504,332,000
  • Beta: 0.83
Profitability:
  • Net Margins: 33.97%
  • Return on Equity: 90.61%
  • Return on Assets: 42.44%
Debt:
  • Current Ratio: 1.26%
  • Quick Ratio: 0.96%
Additional Links:
Companies Related to Novo Nordisk A/S:

Analyst Ratings

Consensus Ratings for Novo Nordisk A/S (NYSE:NVO) (?)
Ratings Breakdown: 2 Sell Ratings, 7 Hold Ratings, 4 Buy Ratings
Consensus Rating:Hold (Score: 2.15)
Consensus Price Target: $57.00 (59.31% upside)

Analysts' Ratings History for Novo Nordisk A/S (NYSE:NVO)
Show:
DateFirmActionRatingPrice TargetDetails
1/3/2017J P Morgan Chase & CoDowngradeNeutral -> UnderweightView Rating Details
12/20/2016Jefferies Group LLCReiterated RatingHoldView Rating Details
12/1/2016Credit Suisse GroupReiterated RatingHoldView Rating Details
10/31/2016DNB MarketsDowngradeBuy -> HoldView Rating Details
10/31/2016Citigroup Inc.DowngradeBuy -> NeutralView Rating Details
10/28/2016Bank of America CorpDowngradeNeutral -> UnderperformView Rating Details
10/13/2016HSBC Holdings plcReiterated RatingHoldView Rating Details
9/23/2016Piper Jaffray CompaniesInitiated CoverageNeutralView Rating Details
9/13/2016BNP ParibasUpgradeNeutral -> OutperformView Rating Details
9/13/2016Pacific CrestUpgradeNeutral -> OutperformView Rating Details
9/12/2016Deutsche Bank AGUpgradeHold -> BuyView Rating Details
9/1/2016Morgan StanleyDowngradeOverweight -> Equal WeightView Rating Details
6/28/2016Goldman Sachs Group, Inc. (The)DowngradeConviction-Buy -> BuyView Rating Details
1/26/2016Oddo SecuritiesUpgradeNeutral -> BuyView Rating Details
9/21/2015SwedbankUpgradeStrong-BuyView Rating Details
8/28/2015Leerink SwannInitiated CoverageMarket Perform$56.00View Rating Details
8/10/2015Main First Bank AGDowngradeHoldView Rating Details
4/15/2015Societe GeneraleInitiated CoverageSellView Rating Details
3/26/2015Bryan, Garnier & CoDowngradeNeutralView Rating Details
(Data available from 2/23/2015 forward)

Earnings

Earnings History for Novo Nordisk A/S (NYSE:NVO)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
4/29/2016Q1$0.53$0.57ViewListenView Earnings Details
10/29/2015Q3$0.47$0.48ViewN/AView Earnings Details
8/6/2015Q215$3.31$3.23$3.98 billion$27.06 billionViewN/AView Earnings Details
4/30/2015Q1$3.20$3.02$25.13 billion$25.20 billionViewN/AView Earnings Details
1/30/2015Q4$2.48$0.38$24.67 billion$24.59 billionViewN/AView Earnings Details
10/30/2014Q3$2.45$2.47$22.25 billion$22.25 billionViewN/AView Earnings Details
8/7/2014Q2$2.60$0.48$21.86 billion$21.63 billionViewN/AView Earnings Details
5/1/2014Q1$2.37$2.43$20.83 billion$20.30 billionViewN/AView Earnings Details
1/28/2014Q413$0.42ViewN/AView Earnings Details
10/31/2013Q1$12.11$2.20$21.04 billion$20.51 billionViewN/AView Earnings Details
8/8/2013Q1$11.97$12.45$21.09 billion$21.38 billionViewN/AView Earnings Details
5/1/2013$10.67$10.98$19.73 billion$19.98 billionViewN/AView Earnings Details
1/31/2013$9.77$10.53$20.83 billion$20.96 billionViewN/AView Earnings Details
10/31/2012Q312$9.43$10.33$57.10 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Novo Nordisk A/S (NYSE:NVO)
Current Year EPS Consensus Estimate: $2.19 EPS
Next Year EPS Consensus Estimate: $2.42 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20163$0.39$0.53$0.48
Q2 20162$0.57$0.58$0.58
Q3 20162$0.54$0.58$0.56
Q4 20162$0.51$0.52$0.52
Q1 20171$0.52$0.52$0.52
Q2 20171$0.52$0.52$0.52
Q3 20171$0.53$0.53$0.53
Q4 20171$0.55$0.55$0.55
(Data provided by Zacks Investment Research)

Dividends

Current Dividend Information for Novo Nordisk A/S (NYSE:NVO)
Annual Dividend:$1.03
Dividend Yield:2.88%
Dividend Growth:31.50% (3 Year Average)
Payout Ratio:46.19% (Based on Trailing 12 Months of Earnings)
47.03% (Based on Current Year Consensus EPS Estimate)
42.56% (Based on Next Year Consensus EPS Estimate)
Track Record:20 Years of Consecutive Dividend Growth

Dividend History for Novo Nordisk A/S (NYSE:NVO)
AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
2/7/2017annual$0.661.99%3/23/20173/27/20174/4/2017
8/8/2016$0.338/11/20168/15/20168/23/2016
2/16/2016Annual$0.703/18/20163/22/20163/30/2016
3/17/2014annual$0.841.83%3/21/20143/25/20144/2/2014
2/27/2013annual$3.181.81%3/21/20133/25/20134/2/2013
(Data available from 1/1/2013 forward)

Insider Trades

Insider Trading History for Novo Nordisk A/S (NYSE:NVO)
Institutional Ownership Percentage: 6.65%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
2/18/2015Richmond Partners Master LimitInsiderSell24,900$1.28$31,876.98
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Novo Nordisk A/S (NYSE:NVO)
DateHeadline
finance.yahoo.com logoSHAREHOLDER ALERT - - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Novo Nordisk A/S (NVO) and Lead Plaintiff Deadline: March 13, 2017 (NYSE:NVO)
finance.yahoo.com - February 23 at 7:01 PM
News IconNovo Nordisk A/S (NYSE:NVO) Equity Price Target Fixed At $36.7 - Transcript Daily (NYSE:NVO)
transcriptdaily.com - February 23 at 12:02 AM
News IconTechnical Trading Review on Shares of Novo Nordisk A/S (NVO) - BVN (NYSE:NVO)
bvnewsjournal.com - February 23 at 12:02 AM
seekingalpha.com logoA Time To Buy Novo Nordisk - Seeking Alpha (NYSE:NVO)
seekingalpha.com - February 23 at 12:02 AM
4-traders.com logoNovo Nordisk A/S : Canadian News Media Challenged to See the Whole Picture When Reporting on Obesity (NYSE:NVO)
www.4-traders.com - February 22 at 7:01 PM
finance.yahoo.com logoCanadian News Media Challenged to See the Whole Picture When Reporting on Obesity (NYSE:NVO)
finance.yahoo.com - February 22 at 7:00 PM
finance.yahoo.com logoNVO INVESTOR ALERT: The Law Offices of Vincent Wong Reminds Investors of Commencement of a Class Action Involving Novo Nordisk A/S and a Lead Plaintiff Deadline of March 13, 2017 (NYSE:NVO)
finance.yahoo.com - February 22 at 7:00 PM
News IconDrug Manufacturers – Other: Novo Nordisk A/S (NYSE:NVO) Position of the day (NYSE:NVO)
twincountynews.com - February 22 at 9:00 AM
News IconJust Published: “Brazil Insulin Delivery Market Outlook to 2022” (NYSE:NVO)
www.ssuchronicle.com - February 20 at 9:45 AM
sbwire.com logoNew Market Research Report: United Kingdom Insulin Delivery Market Outlook to 2022 (NYSE:NVO)
www.sbwire.com - February 20 at 9:45 AM
globenewswire.com logoNovo Nordisk A/S - Share repurchase programme (NYSE:NVO)
globenewswire.com - February 20 at 9:45 AM
finance.yahoo.com logoSHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Novo Nordisk ... - Yahoo Finance (NYSE:NVO)
finance.yahoo.com - February 19 at 5:57 PM
nasdaq.com logoCardinal Capital Management Buys Novo Nordisk A/S, Envision Healthcare, Rocky Mountain ... (NYSE:NVO)
www.nasdaq.com - February 18 at 6:07 PM
businesswire.com logoNOVO NORDISK SHAREHOLDER ALERT by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Reminds Investors with Losses in Excess of $100,000 of Lead Plaintiff Deadline in ... (NYSE:NVO)
www.businesswire.com - February 18 at 11:52 AM
finance.yahoo.com logoNOVO NORDISK SHAREHOLDER ALERT by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Reminds Investors with Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Novo Nordisk A/S – (NVO) (NYSE:NVO)
finance.yahoo.com - February 18 at 11:52 AM
News IconAre Analysts Optimistic About Where Novo Nordisk A/S (NYSE:NVO) is Heading? - Winfield Review (NYSE:NVO)
winfieldreview.com - February 17 at 4:36 PM
finance.yahoo.com logoINVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Novo Nordisk A/S of a Class Action Lawsuit and a Lead Plaintiff Deadline of March 13, 2017 (NYSE:NVO)
finance.yahoo.com - February 17 at 4:36 PM
businesswire.com logoDEADLINE ALERT: Brower Piven Alerts Shareholders Of Approaching Deadline In Class Action Lawsuit And Encourages Those With Losses In Excess Of $100,000 From Investment In Novo ... (NYSE:NVO)
www.businesswire.com - February 14 at 10:08 PM
finance.yahoo.com logoSHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Novo Nordisk A/S (NVO) and Lead Plaintiff Deadline: March 13, 2017 (NYSE:NVO)
finance.yahoo.com - February 14 at 10:08 PM
finance.yahoo.com logoNVO INVESTORS ALERT: Lieff Cabraser Announces Securities Class Action Against Novo Nordisk A/S (NYSE:NVO)
finance.yahoo.com - February 14 at 10:08 PM
finance.yahoo.com logoDEADLINE ALERT: Brower Piven Alerts Shareholders Of Approaching Deadline In Class Action Lawsuit And Encourages Those With Losses In Excess Of $100,000 From Investment In Novo Nordisk A/S To Contact The Firm (NYSE:NVO)
finance.yahoo.com - February 14 at 10:08 PM
4-traders.com logoNovo Nordisk A/S : - Share repurchase programme (NYSE:NVO)
www.4-traders.com - February 14 at 1:07 AM
4-traders.com logoNovo Nordisk A/S : Whitehouse Laboratories to Co-Present with Novo Nordisk at PDA Parenteral Packaging Conference (NYSE:NVO)
www.4-traders.com - February 13 at 8:06 PM
finance.yahoo.com logoNVO SHAREHOLDER ALERT: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving Novo Nordisk A/S and a Lead Plaintiff Deadline of March 13, 2017 (NYSE:NVO)
finance.yahoo.com - February 13 at 8:06 PM
seekingalpha.com logoNovo Nordisk - From Growth To Value? - Seeking Alpha (NYSE:NVO)
seekingalpha.com - February 13 at 9:44 AM
finance.yahoo.com logoSHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Novo Nordisk A/S of Class Action Lawsuit and Upcoming Deadline – NVO (NYSE:NVO)
finance.yahoo.com - February 11 at 12:55 AM
finance.yahoo.com logoSHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Novo Nordisk A/S (NVO) and Lead Plaintiff Deadline - March 13, 2017 (NYSE:NVO)
finance.yahoo.com - February 10 at 7:53 PM
News IconLeading stocks in today’s market: Novo Nordisk A/S (NYSE:NVO) (NYSE:NVO)
twincountynews.com - February 9 at 8:02 PM
finance.yahoo.com logoGreat Place to Work® and Fortune Name Novo Nordisk as one of the country's best workplaces for giving back (NYSE:NVO)
finance.yahoo.com - February 9 at 8:02 PM
sg.finance.yahoo.com logoDenmark joins race to host EU drug agency instead of London after Brexit (NYSE:NVO)
us.rd.yahoo.com - February 9 at 12:50 AM
gurufocus.com logoEQUITY ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Novo Nordisk A/S â ... - GuruFocus.com (NYSE:NVO)
www.gurufocus.com - February 8 at 7:50 PM
globenewswire.com logoNVO INVESTOR ALERT: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving Novo Nordisk ... - GlobeNewswire (press release) (NYSE:NVO)
globenewswire.com - February 8 at 7:50 PM
feeds.benzinga.com logoNVO INVESTOR ALERT: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving Novo Nordisk A/S and a Lead Plaintiff Deadline of March 13, 2017 (NYSE:NVO)
feeds.benzinga.com - February 8 at 3:26 PM
globenewswire.com logoTrading in Novo Nordisk shares by board members, executives and associated ... (NYSE:NVO)
globenewswire.com - February 7 at 9:30 PM
us.rd.yahoo.com logoBeaten-Down Valuation and a 3% Dividend Yield (NYSE:NVO)
us.rd.yahoo.com - February 7 at 9:30 PM
finance.yahoo.com logoSHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Novo ... - Yahoo Finance (NYSE:NVO)
finance.yahoo.com - February 7 at 4:29 PM
News IconImpact Score Of Novo Nordisk A/S (NYSE:NVO) At 0 - Stock Observer (NYSE:NVO)
www.thestockobserver.com - February 7 at 4:29 PM
globenewswire.com logoEQUITY ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Novo Nordisk A/S – NVO - GlobeNewswire (press release) (NYSE:NVO)
globenewswire.com - February 7 at 4:29 PM
investopedia.com logoHemophilia Drug Market Competitive Ramps Up (NYSE:NVO)
www.investopedia.com - February 7 at 4:29 PM
finance.yahoo.com logoEQUITY ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Novo Nordisk A/S – NVO (NYSE:NVO)
finance.yahoo.com - February 7 at 4:29 PM
capitalcube.com logoNovo Nordisk A/S :NVO-US: Earnings Analysis: 2016 By the Numbers : February 7, 2017 (NYSE:NVO)
www.capitalcube.com - February 7 at 4:29 PM
News IconNovo Nordisk A/S (NYSE:NVO) reported Sales of 15.97 Billion - The Newburgh Press (NYSE:NVO)
newburghpress.com - February 7 at 12:04 AM
News IconStock Price of Novo Nordisk A/S (NVO) Decreases -4.75% - Highland Mirror (NYSE:NVO)
www.highlandmirror.com - February 7 at 12:04 AM
capitalcube.com logoNovo Nordisk A/S :NVO-US: Earnings Analysis: Q4, 2016 By the Numbers : February 6, 2017 (NYSE:NVO)
www.capitalcube.com - February 6 at 7:01 PM
finance.yahoo.com logoValue Screeners Identify Top Sectors (NYSE:NVO)
finance.yahoo.com - February 6 at 7:01 PM
News IconWhat should you know before buying Novo Nordisk A/S (NVO) for its dividend (NYSE:NVO)
simplywall.st - February 5 at 6:44 PM
finance.yahoo.com logoSHAREHOLDER ALERT: CLASS PERIOD EXPANDED IN CLASS ACTION LAWSUIT – Brower Piven Encourages ... - Yahoo Finance (NYSE:NVO)
finance.yahoo.com - February 4 at 5:44 AM
prnewswire.com logoSHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Novo Nordisk ... - PR Newswire (press release) (NYSE:NVO)
www.prnewswire.com - February 4 at 5:44 AM
News IconNovo Nordisk A/S (NYSE:NVO) EPS Projection Set At $0.52 - Transcript Daily (NYSE:NVO)
transcriptdaily.com - February 4 at 12:43 AM
finance.yahoo.com logoSHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Novo Nordisk A/S of a Class Action Lawsuit ... - Yahoo Finance (NYSE:NVO)
finance.yahoo.com - February 4 at 12:43 AM

Social

What is Novo Nordisk A/S's stock symbol?

Novo Nordisk A/S trades on the New York Stock Exchange (NYSE) under the ticker symbol "NVO."

How often does Novo Nordisk A/S pay dividends? What is the dividend yield for Novo Nordisk A/S?

Novo Nordisk A/S declared an annual dividend on Tuesday, February 7th. Stockholders of record on Monday, March 27th will be paid a dividend of $0.6634 per share on Tuesday, April 4th. This represents a dividend yield of 1.99%. The ex-dividend date of this dividend is Thursday, March 23rd.

Where is Novo Nordisk A/S's stock going? Where will Novo Nordisk A/S's stock price be in 2017?

13 brokerages have issued 1 year price objectives for Novo Nordisk A/S's shares. Their forecasts range from $57.00 to $57.00. On average, they expect Novo Nordisk A/S's stock price to reach $57.00 in the next year.

Who owns Novo Nordisk A/S stock?

Novo Nordisk A/S's stock is owned by many different of retail and institutional investors. Top institutional investors include Loomis Sayles & Co. L P (0.76%), Renaissance Technologies LLC (0.56%), FMR LLC (0.24%), Santa Barbara Asset Management LLC (0.09%), Capital Guardian Trust Co. (0.05%) and Franklin Resources Inc. (0.04%).

Who sold Novo Nordisk A/S stock? Who is selling Novo Nordisk A/S stock?

Novo Nordisk A/S's stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Renaissance Technologies LLC, Franklin Resources Inc., Artisan Partners Limited Partnership, First Republic Investment Management Inc., Ruane Cunniff & Goldfarb Inc., Teachers Retirement System of The State of Kentucky and Scotia Capital Inc..

Who bought Novo Nordisk A/S stock? Who is buying Novo Nordisk A/S stock?

Novo Nordisk A/S's stock was purchased by a variety of institutional investors in the last quarter, including Loomis Sayles & Co. L P, Russell Investments Group Ltd., Two Sigma Investments LP, Hutchinson Capital Management CA, Marshall Wace LLP, Cutter & CO Brokerage Inc., Envestnet Asset Management Inc. and Headinvest LLC.

How do I buy Novo Nordisk A/S stock?

Shares of Novo Nordisk A/S can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Novo Nordisk A/S stock cost?

One share of Novo Nordisk A/S stock can currently be purchased for approximately $35.78.

Novo Nordisk A/S (NYSE:NVO) Chart for Thursday, February, 23, 2017


Institutional Ownership Chart

Institutional Ownership by Quarter for Novo Nordisk A/S (NYSE:NVO)

Earnings History Chart

Earnings by Quarter for Novo Nordisk A/S (NYSE:NVO)

Dividend History Chart

Dividend Payments by Quarter for Novo Nordisk A/S (NYSE:NVO)

Last Updated on 2/23/2017 by MarketBeat.com Staff